Acumulado Enero - Diciembre 2023 (93 - 96) N°93
ISSN 1317-987X
 
Buscar




De interés
 
Abreviaturas, Introducción y Objetivos
Cuándo iniciar la terapia antiretroviral
Recomendaciones para tratamiento antirretroviral de primera línea
Razones para cambiar el tratamiento antiretroviral
Seguimiento clínico y de laboratorio
Opciones de tratamiento antirretroviral de segunda línea
Consideraciones para categorías especificas de pacientes: Mujeres en edad fértil o embarazadas y niños
Consideraciones para categorías especificas de pacientes: Enfermos de tuberculosis y Usuarios de drogas inyectables
Cumplimiento del tratamiento antirretroviral
Vigilancia de la resistencia farmacológica
Conclusiones
Apéndices
Referencias





Expansión del tratamiento antirretrovial en entornos de recursos limitados

Referencias

  1. Palella FJ, Jr., Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. Apr 15 2003;138(8):620-626.
  2. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Jama. Jul 10 2002;288(2):222-235.
  3. DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://AIDSInfo.nih.gov/guidelines.
  4. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. Aids. Mar 7 2003;17(4):541-545.
  5. Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, Thyagarajan SP, Solomon S. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr. Dec 1 2002;31(4):378-383.
  6. Van der Ryst E, Kotze M, Joubert G, Steyn M, Pieters H, van der Westhuizen M, van Staden M, Venter C. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. J Acquir Immune Defic Syndr Hum Retrovirol. Nov 1 1998;19(3):238-244.
  7. Brettle RP. Correlation between total and CD4 lymphocyte counts in HIV infection. Int J STD AIDS. Sep 1997;8(9):597.
  8. Beck EJ, Kupek EJ, Gompels MM, Pinching AJ. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS. Oct 1996;7(6):422-428.
  9. Fournier AM, Sosenko JM. The relationship of total lymphocyte count to CD4 lymphocyte counts in patients infected with human immunodeficiency virus. Am J Med Sci. Aug 1992;304(2):79-82.
  10. Bang LM, Scott LJ. Emtricitabine: an antiretroviral agent for HIV infection. Drugs.2003;63(22):2413-2424; discussion 2425-2416.
  11. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. Dec 2001; 33 (11): 1931-1937.
  12. Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retroviruses. Jul 1 2002; 18(10):699-704.
  13. Staszewski S GJ, Pozniak AL, Suleiman JMAH, DeJesus E, Lu B, Sayre J, Cheng A. Efficacy and safety of tenofovir DF versus stavudine when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston , MA .
  14. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. Oct 1 2003;37(7):944-950.
  15. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases ofrenal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. Apr 15 2003;36(8):1070-1073.
  16. Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. Aug 1 2003;37(3):e41-43.
  17. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. Dec 2002;40(6):1331-1333.
  18. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. Nov 2003;14(11):776-781.
  19. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenzcontaining antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. Jul-Aug 2002;3(4):296-303.
  20. Keiser P, Nassar N, Yazdani B, Armas L, Moreno S. Comparison of efficacy of efavirenz and nevirapine: lessons learned for cohort analysis in light of the 2NN Study. HIV Clin Trials. Sep-Oct 2003;4(5):358-360.
  21. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIVNAT Cohort, Thailand, 1996-2001. Aids. Oct 17 2003;17(15):2191-2199.
  22. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. Mar-Apr 2003;4(2):115-120.
  23. Moyle GJ. NNRTI choice: has 2NN changed our practice? AIDS Read. Jul 2003;13(7):325-328.
  24. Van Leth F HE, Phanuphak P, Miller S, Gazzard B, Cahn P, Wood R, Squires K, Katlama C, Santos B, Robinson P, van Leeuwen R, Wit F, Lange J. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone, or both drugs combined, together with stavudine and lamivudine. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston , MA
  25. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA , Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. Jul 1 2003;37(1):113-128.
  26. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. Jun 27 2002;346(26):2039-2046.
  27. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. Jan 1 2003;32(1):18-29.
  28. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, Sension M. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. Aids. Jun 13 2003;17(9):1339-1349.
  29. Piliero PJ. Atazanavir: a novel HIV-1 protease inhi bitor. Expert Opin Investig Drugs. Sep 2002;11(9):1295-1301.
  30. Gulick RM RH, Shikuma CM, Lustgarten S, Meyer WA, Klingman K, Squires KE, Snyder S, Kuritzkes DR. ACTG 5095: a comparative sutdy of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. Paper presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris , FR.
  31. Gallant JE RA, Weinberg W, Young B, Berger D, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS. Early non-response to tenofovir DF and abacavir and lamivudine in a randomized trial compared to efavirenz + ABC and 3TC: ESS30009 unplanned interim analysis. Paper presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago , IL .
  32. Gilead . High rate of virologic failure in patients with HIV infection treated with once daily triple NRTI regimen containing didanosine, lamivudine, and tenofovir; 2003.
  33. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. Aids. Sep 26 2003; 17 (14): 2045-2052.
  34. Havlir D, Vella S, Hammer S. The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society. Aids. Jul 5 2002; 16 (10): 7-9.
  35. UNAIDS. AIDS Epidemic Update: December 2003 (in press)
  36. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan , Cote d'Ivoire . AIDS 2003; 17(suppl 3):S49-S54.
  37. Van der Ende ME, Prins JM, Brinkman K, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003;17(suppl 3):S55-S61.
  38. Smith NA, Shaw T, Berry N, et al. Antiretroviral therapy for HIV-2-infected patients. J Infect 2001;42:126-33.
  39. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003, 17 (suppl 3):S103-S108.
  40. Access to antiretroviral drugs and AIDS management in Senegal . AIDS 2003, 17 (suppl 3):S95-S101
  41. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994;13:2359-67.
  42. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 Study. J Allergy Clin Immunol 2003, in press.
  43. Embree J, Bwayo J, Nagelkerke N, et al. Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi . Pediatr Infect Dis J 2001;20:397-403.
  44. Mofenson LM, Harris DR , Moye J, et al. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. Lancet 2003, in press.
  45. European Collaborative Study. Gender and race do not alter early-life determinants of clinical disease progression in HIV-1 vertically infected children. AIDS 2003, in press.
  46. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
  47. De Martino M, Tovo P-A, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190-7.
  48. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;184:914-7.
  49. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93.
  50. Lindsey JC, Hughes MD, McKinney RE, et al. Treatment mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis 2000;182:1385-93.
  51. Verweel G, van Rossum AMC, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002;109 (2): URL: http://www.pediatrics.org/cgi/content/full/109/2/e25.
  52. Saulsbury FT. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis 2001;32:464-8
  53. McCoig C, Castrejon MM, Castano E, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr 2002;141:36-44.
  54. Stern JO, Love JT, Robinson, PA, et al. Hepatic safety of nevirapine: Results of the Boehringer Ingelheim Viramune Hepatic Safety Project. 14 th International Conference on AIDS. Barcelona , Spain . July 7-12, 2002 (abstract LBOr15).
  55. Imperiale SM, Stern JO, Love JT, et al. The VIRAMUNE (nevirapine) hepatic safety project:analysis of symptomatic hepatic events. 4 th International Workshop on Adverse Events and Lipodystrophy in HIV. San Diego , CA. September 22-25, 2002 (abstract 87).
  56. Stern JO, Robinson PA, Love JT, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. JAIDS 2003;34:S21-33.
  57. Boehringer-Ingelheim Pharmaceuticals, Inc. Viramune drug label. Revised June 20, 2003.
  58. Lyons F, Hopkins S, McGeary A et al. Nevirapine tolerability in HIV infected women in pregnancy – A word of caution. 2 nd IAS Conference on HIV Pathogenesis and Treatment. Paris , France . July 13-16, 2003 (late breaker).
  59. Langlet P, Guillaume M-P, Devriendt J, et al. Fatal liver failure associated with nevirapine in a pregnant HIV patient: the first reported case. Gastroenterol 2000;118 (suppl 2):Abs 6623 (101 st Annual Meeting of the American Gastroenterological Association, San Diego , May 21-24, 2000).
  60. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;184:914-7.
  61. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93.
  62. Sullivan J. South African Intrapartum Nevirapine Trial: selection of resistance mutations. XIV International Conference on AIDS. Barcelona , Spain , July 7-12, 2002 (Abs. LbPeB9024).
  63. Cunningham C,K, Chaix ML, Rackacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group protocol 316. J Infect Dis 2002; 186:181-8.
  64. Chaowanachan T, Chotpitayasunondh T, Vanprapar N, et al. Resistance mutations following a single-dose intrapartum administration of nevirapine to HIV-infected Thai women and their infants receiving short-course zidovudine. 10 th Conference on Retroviruses and Opportunistic Infections. Boston , MA , February 10-14, 2003 (Abs. 855).
  65. Giuliano M, Palmisano L, Galluzzo CM, et al. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 2003;17:1570-1.
  66. Santoro-Lopes G. de Pinho AM. Harrison LH. Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clinical Infectious Diseases. 34(4):543-6, 2002.
  67. Giarardi E, Antonucci G, Vanacore P et al. Impact of combination antireteroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS; 14:1985-91, 2000
  68. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa : a cohort study. Lancet;359:2059-64, 2002
  69. Harvard University. Consensus statement on antiretroviral treatment for AIDS in poor countries, Boston , Harvard University , 2001.
  70. Burman WJ. Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. American Journal of Respiratory & Critical Care Medicine. 164(1):7-12, 2001.
  71. Wagner KR. Bishai WR. Issues in the treatment of Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. AIDS. 15 Suppl 5:S203-12, 2001.
  72. Havlir DV. Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. New England Journal of Medicine. 340(5):367-73, 1999
  73. Dean GL. Edwards SG. Ives NJ . Matthews G. Fox EF. Navaratne L. Fisher M. Taylor GP. Miller R. Taylor CB. de Ruiter A. Pozniak AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 16(1):75-83, 2002.
  74. Lopez-Cortes L, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002;41:681-690.
  75. Patel A, Patel K, Patel J, et al. To study the safety and antiretroviral efficacy of rifampicin and efavirenz in antiretroviral-naïve tuberculosis co-infected HIV-1 patients in India . X Conference on Retroviruses and Opportunistic Infections, Boston , MA . 2003: abstract 138.
  76. Pedral-Samapio D, Alves C, Netto E, et al. Efficacy of efavirenz 600 mg dose in the ARV therapy regimen for HIV patients receiving rifampicin in the treatment of tuberculosis. X Conference on Retroviruses and Opportunistic Infections, Boston , MA . 2003: abstract 784.
  77. Dean G, Back D, de Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentration (correspondence). AIDS 1999;13:2489-2490.
  78. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevaripine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Synr 2001; 28:450-453.
  79. Olivia J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis (correspondence). AIDS 2003;17:637-642.
  80. Ribera E., Azuaje C., Montero F. Saquinavir, ritonavir, didanosine, and lamivudine in a once daily regimen for HIV infection in patients with rifampin-containing antituberculosis treatment. XVI International AIDS Conference. Barcelona , Spain 2002. abstract ThPeB7280
  81. La Porte C , Colbers E, Bertz R, et al. Pharmacokinetics of two adjusted dose regimens of lopinavir/ritonavir in combination with rifampin in healthy volunteers. 42 nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego , CA 2002: abstract #A-1823.
  82. Narita M, Ashkin D, Hollander E, Pitchenik A. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 158:157-161 . 1998
  83. Harries AD. Hargreaves NJ . Kemp J. Jindani A. Enarson DA. Maher D. Salaniponi FM. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 357(9267):1519-23, 2001.
  84. Kityo C. A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa : The DART trial. 13 th International Conference on AIDS and STIs in Africa (ICASA). Nairobi , Kenya 2003, abstract 1098933.
  85. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavirlamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA. 2001 Mar 7;285(9):1155-63.
  86. Ibbotson T, Perry CM. Lamivudine/zidovudine/abacavir: triple combination tablet. Drugs . 2003; 63(11):1089-98; discussion 1099-1100.
Abreviaturas, Introducción y Objetivos
Cuándo iniciar la terapia antiretroviral
Recomendaciones para tratamiento antirretroviral de primera línea
Razones para cambiar el tratamiento antiretroviral
Seguimiento clínico y de laboratorio
Opciones de tratamiento antirretroviral de segunda línea
Consideraciones para categorías especificas de pacientes: Mujeres en edad fértil o embarazadas y niños
Consideraciones para categorías especificas de pacientes: Enfermos de tuberculosis y Usuarios de drogas inyectables
Cumplimiento del tratamiento antirretroviral
Vigilancia de la resistencia farmacológica
Conclusiones
Apéndices
Referencias

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit